This inventor holds 2 USPTO granted patents. Top assignee: Wuhan Yzy Biopharma Co., Ltd.. Active years: 2017-2018.
Location History:
- Hubei, CN (2017)
- Wuhan, CN (2018)
Company Filing History:
Years Active: 2017-2018
Title: Innovations by Inventor Kesu Fan in the Field of Biopharmaceuticals
Introduction
Kesu Fan is a notable inventor based in Wuhan, China, recognized for his contributions to biopharmaceutical innovations. With two patents to his name, he has made significant strides in the development of bispecific antibodies, which hold promising therapeutic potential against cancer.
Latest Patents
One of Kesu Fan's latest patents focuses on the "Construction and application of bispecific antibody HER2xCD3." This invention presents a bispecific antibody that consists of a single-chain unit and a monovalent unit. The single-chain unit is designed to have a specific binding capability against the CD3 surface antigen found on immune cells, while the monovalent unit is targeted against the HER2 surface antigen in tumor cells. The single-chain unit includes a single-chain variable fragment (ScFv) fused with an Fc fragment, and the monovalent unit is made up of a light chain and heavy chain pair. Additionally, the patent outlines the preparation method for this bispecific antibody and its pharmaceutical applications.
Career Highlights
Kesu Fan is affiliated with Wuhan Yzy Biopharma Co., Ltd., a company dedicated to advancing biopharmaceutical technologies. His work at the company has enabled the exploration of new therapeutic approaches leveraging bispecific antibodies, positioning him as an influential figure in the field of immunotherapy.
Collaborations
In his pursuit of innovation, Kesu Fan collaborates with talented colleagues including Pengfei Zhou and Jing Zhang. Their collective efforts contribute to the research and development initiatives at Wuhan Yzy Biopharma Co., Ltd., enhancing the potential for breakthroughs in cancer treatment methodologies.
Conclusion
Kesu Fan's innovative work on bispecific antibodies exemplifies the intersection of science and medicine. His patents not only reflect his expertise in biopharmaceuticals but also highlight a commitment to improving patient outcomes. As research advances, the impact of his inventions may contribute significantly to the future of cancer therapy.